A systematic review of re-induction chemotherapy for children with relapsed high-risk neuroblastoma.

Despite aggressive multimodal therapy, >50% of children with high-risk neuroblastoma (HRNB) relapse. Survival after relapse is rare, and no consensus currently exists on the most effective therapy.